Dementia and Alzheimer Disease

Sharon Cohen, MD, and Marwan Sabbagh, MD, discuss the current understanding of tau as a marker of neuronal injury and its role in the pathophysiology of Alzheimer's disease, particularly focusing on the significance of phosphorylated tau and neurofibrillary tangles in the disease process.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Huntington disease.

Neurology News Network. for the week ending May 18, 2024. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 17, 2024.

Voyager expects insights from the phase 1a study to inform a subsequent phase 1b trial and anticipates tau PET imaging data in 2026.

The subcutaneous autoinjector, which facilitates 360 mg weekly maintenance dosing of lecanemab, takes less time to administer than the approved intravenous formulation and may lead to less hospital visits and nursing care.

The director of the Brain Health Imaging Institute in the department of radiology at Weill Cornell Medicine talked about exploring nasal pathways as an alternative for brain protein sampling and drug delivery. [WATCH TIME: 4 minutes]

Panelists delve into the amyloid cascade hypothesis of Alzheimer's disease and the ongoing debate surrounding it, discussing the presence and potential roles of Aβ monomers, oligomers, protofibrils, and amyloid plaques in patients with Alzheimer's disease.

The panel provides an overview of amyloid precursor protein (APP) and the generation of amyloid β (Aβ) peptides, Aβ42 and Aβ40, while also discussing which soluble or insoluble Aβ species (monomers, oligomers, protofibrils, or amyloid plaques) contribute to neuronal damage and the clinical manifestation of Alzheimer's disease.

Here's some of what is coming soon to NeurologyLive® this week.

Bezisterim-treated patients showed age deceleration across various DNA methylation clocks, indicating potential anti-aging effects.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on cluster headache.

Neurology News Network. for the week ending May 11, 2024. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 10, 2024.

The director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester discussed treatment response and safety findings from the phase 3 ACCORD study assessing AXS-05 for agitation in Alzheimer disease. [WATCH TIME: 6 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of April 2024, compiled all into one place by the NeurologyLive® team.

The FDA AdComm will deliberate over the phase 3 TRAILBLAZER-ALZ 2 trial, a large-scale study that assessed the efficacy and safety of donanemab in patients with early-stage Alzheimer disease over an 18-month period.

The phase 1 open-label, dose-escalation study will include 9 participants with mild-to-moderate Alzheimer disease whose treatment is not addressed adequately by available therapy.

Neal K. Shah, CEO of CareYaya Health Technologies, discussed how Apple's expected announcement of new iPads with OLED displays could revolutionize cognitive health and dementia care for older adults.

Key opinion leaders emphasize the significance of early diagnosis in Alzheimer's disease, as it allows patients to make autonomous decisions and access early treatment options, including potential participation in clinical trials.

Sharon Cohen, MD, and Marwan Sabbagh, MD, differentiate between the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD), and highlight known risk factors, including the contribution of ApoE gene polymorphism and copy numbers.

Here's some of what is coming soon to NeurologyLive® this week.

A recent case series showed concerning trends of neurological conditions from mosquito-borne diseases impacting patients living in Canada and the United States.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on treatment-refractory epilepsy.